Información de Jazz Pharmaceuticals PLC, dividendo de Jazz Pharmaceuticals PLC, actividades de los accionistas y más

Más Datos de Jazz Pharmaceuticals PLC Compañía

Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Información de Jazz Pharmaceuticals PLC



Símbolo de cotizaciónJAZZ

Nombre de la empresaJazz Pharmaceuticals PLC

Fecha de salida a bolsaJan 18, 2012

Director ejecutivoGala (Renee D)

Número de empleados2800

Tipo de seguridadOrdinary Share

Fin del año fiscalJan 18

DirecciónFifth Floor, Waterloo Exchange

CiudadDUBLIN

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísIreland

Código postal- -

Teléfono35316347800

Sitio Webhttps://www.jazzpharma.com/

Símbolo de cotizaciónJAZZ

Fecha de salida a bolsaJan 18, 2012

Director ejecutivoGala (Renee D)

Ejecutivos de Jazz Pharmaceuticals PLC



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Seamus C. Mulligan

Independent Director

1.28M

+3507.00%

Mr. Bruce C. Cozadd

Chairman of the Board

310.79K

+18464.00%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

55.49K

+7370.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.68K

+7559.00%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

27.20K

+5577.00%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

--

Dr. Norbert G. Riedel, Ph.D.

Independent Director

13.92K

+1702.00%

Ms. Anne O'Riordan

Independent Director

12.77K

+1702.00%

Ms. Samantha Pearce

Executive Vice President, Chief Commercial Officer

11.28K

+2038.00%

Ms. Jennifer E. Cook

Independent Director

7.11K

+1702.00%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Seamus C. Mulligan

Independent Director

1.28M

+3507.00%

Mr. Bruce C. Cozadd

Chairman of the Board

310.79K

+18464.00%

Ms. Renee D. Gala

President, Chief Executive Officer, Director

55.49K

+7370.00%

Dr. Robert Iannone, M.D.

Executive Vice President, Global Head - Research and Development, Chief Medical Officer

31.68K

+7559.00%

Ms. Neena M. Patil, J.D.

Executive Vice President, Chief Legal Officer

27.20K

+5577.00%

Mr. Philip L. Johnson

Chief Financial Officer, Executive Vice President

15.00K

--

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Xywav

431.41M

38.31%

Epidiolex/epidyolex

302.61M

26.87%

Rylaze

99.87M

8.87%

Zepzelca

79.30M

7.04%

High-sodium oxybate AG royalty revenue

52.95M

4.70%

Otro

159.98M

14.21%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

1.02B

90.62%

Europe

86.41M

7.67%

All Others

19.23M

1.71%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Xywav

431.41M

38.31%

Epidiolex/epidyolex

302.61M

26.87%

Rylaze

99.87M

8.87%

Zepzelca

79.30M

7.04%

High-sodium oxybate AG royalty revenue

52.95M

4.70%

Otro

159.98M

14.21%

Estadísticas de accionistas

Actualizado: jue., 4 de dic

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

9.70%

BlackRock Institutional Trust Company, N.A.

8.25%

Dimensional Fund Advisors, L.P.

4.67%

Capital World Investors

4.20%

LSV Asset Management

4.04%

Otro

69.14%

Accionistas

Proporción

The Vanguard Group, Inc.

9.70%

BlackRock Institutional Trust Company, N.A.

8.25%

Dimensional Fund Advisors, L.P.

4.67%

Capital World Investors

4.20%

LSV Asset Management

4.04%

Otro

69.14%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

50.47%

Investment Advisor/Hedge Fund

34.46%

Hedge Fund

10.57%

Research Firm

3.49%

Individual Investor

3.09%

Pension Fund

1.75%

Venture Capital

1.30%

Bank and Trust

1.13%

Family Office

0.10%

Participación institucional



Actualizado: jue., 1 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

1196

62.93M

103.56%

-8.99M

2025Q3

1197

64.03M

105.38%

-5.21M

2025Q2

1199

63.76M

105.11%

-6.47M

2025Q1

1235

63.66M

105.15%

-6.35M

2024Q4

1202

62.66M

103.17%

-6.51M

2024Q3

1172

61.48M

99.60%

-6.16M

2024Q2

1167

61.28M

97.21%

-6.97M

2024Q1

1163

63.08M

101.15%

-2.43M

2023Q4

1156

61.76M

98.11%

-3.48M

2023Q3

1158

61.08M

96.76%

-4.05M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

5.88M

9.68%

-184.81K

-3.05%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

5.01M

8.25%

-208.46K

-3.99%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

2.84M

4.67%

+298.81K

+11.77%

Sep 30, 2025

Capital World Investors

2.55M

4.2%

+10.35K

+0.41%

Sep 30, 2025

LSV Asset Management

2.51M

4.13%

-41.88K

-1.64%

Sep 30, 2025

State Street Investment Management (US)

1.87M

3.07%

-67.50K

-3.49%

Sep 30, 2025

EcoR1 Capital, LLC

1.71M

2.81%

--

Sep 30, 2025

JP Morgan Asset Management

1.70M

2.8%

+152.32K

+9.83%

Sep 30, 2025

Fuller & Thaler Asset Management Inc.

1.63M

2.68%

-2.82K

-0.17%

Sep 30, 2025

Columbia Threadneedle Investments (US)

1.57M

2.58%

+29.17K

+1.89%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

Cambria Cannabis ETF

4.08%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

3.11%

iShares U.S. Pharmaceuticals ETF

3.08%

Invesco Pharmaceuticals ETF

2.94%

State Street SPDR S&P Pharmaceuticals ETF

2.83%

Abacus FCF International Leaders ETF

2.69%

First Trust NASDAQ Pharmaceuticals ETF

2.51%

Clough Hedged Equity ETF

2.4%

Alger Russell Innovation ETF

2.12%

VictoryShares Small Cap Free Cash Flow ETF

1.77%

Cambria Cannabis ETF

Proporción4.08%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción3.11%

iShares U.S. Pharmaceuticals ETF

Proporción3.08%

Invesco Pharmaceuticals ETF

Proporción2.94%

State Street SPDR S&P Pharmaceuticals ETF

Proporción2.83%

Abacus FCF International Leaders ETF

Proporción2.69%

First Trust NASDAQ Pharmaceuticals ETF

Proporción2.51%

Clough Hedged Equity ETF

Proporción2.4%

Alger Russell Innovation ETF

Proporción2.12%

VictoryShares Small Cap Free Cash Flow ETF

Proporción1.77%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos